- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06623916
Strain-elastography in Endometrial Cancer
Can Elastographic Evaluation Be a New Approach in Prediction of Endometrial Cancer Prognostic Markers?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Endometrial cancer is the most common gynecologic cancer, particularly in developed countries of the World. Today, it ranks as the 4th most common cancer among the women after breast, colorectal and lung malignencies. Although 4% of patients are premenopausal, most common symptom of disease is postmenopausal bleeding. Obtaining pathological sample as an endometrial Pipelle Biopsy, dilatation-curettage or hysterescopic excision are main diagnostic methods in endometrial cancer. Prognosis of disease depends on age, grade, myometrial invasion-histologic type of tumor, lymph node and distant metastasis.
In addition to pathologic reports; transvaginal ultrasound is most commonly used preoperative non invasive, no radiation-related and low cost imaging method to assess the endometrial cavity, endo-myometrial invasion, tumor diameter, cervical and adnexal involvement. Some of these risk factors can be easily detected with transvaginal ultrasound as well as intraoperative frozen-section examination.
Sonoelastography is a novel technique, which evaluate tissue stiffness both qualitatively and quantitatively and can distinguish different lesions in various organs as liver, breast and thyroid. Strain and shear-wave imagings are two main elastographic technics that commonly used with ultrasound technology. In the first method, the operator exerts manual compression on the tissue with the ultrasound transducer. Strain elastography evaluates the tissue elasticity by measuring the degree of distorsion by the compression and decompression of soft tissues and strain ratio (SR) is obtained by proportioning the tissue elasticity of the suspicious pathologic area with a reference point. Manual compression works fairly well for superficial organs such as the breast, superficial lymph nodes and thyroid but is challenging for assessing elasticity in deeper located organs such as the liver. Strain elastography is a semi-quantitative method due to the variations in compression and decompression pressures and selected ROI areas between practitioners. The use of SR makes this relative subjective technic more objective. In shear wave elastography, the ultrasound transducer is held steady, and tissue displacement is generated by internal physiologic motion (e.g. cardiovascular, respiratory). Since this method is not dependent on superficially applied compression, variations between practitioners are negligible and it may be used to assess deeper located organs.
In gynecology clinical practice, sono elastography has been used in recent years in different subjects as ovarian and endometrial benign lesions. In diagnostic process, elastography is not been well established in endometrial cancer.
In this study, we aimed to determine whether sonoelastography could be a new prognostic predictor in endometrial cancer. Accordingly, we examined the relationship between the elastographic features of the lesions and known pathologic prognostic factors in endometrial cancer cases.
Inform consent was provided from all patients before evaluation. Biopsy-confirmed ( Pipelle sampling or dilatation and curettage ) 90 endometrial cancer patients were evaluated. Diagnosis of different types of tumors in the last 5 years, presence of synchronous malignancy, presence of non epithelial uterine tumor, lack of patient data, presence of full-thickness uterine and cervical involvement (lack of evaluation for elastography), lack of patient compliance for transvaginal ultrasound and inoperable cases (lack of definitive pathologic report) were the exclusion criterias of the study. Demographic and clinical datas were collected through a questionnaire including age, gravida, parity, weight (kg), height (cm). Body mass index (BMI)was calculated as a kg/ cm2. Cancer Antigen-125(CA-125) values were recorded as a IU/ml. Positron emission tomography/computed tomography (PET/CT) imaging was performed before surgery for evaluating of distant metastasis and excluding inoperable patients. Standardized Uptake Values (SUV)-max value of tumor in uterus was recorded. 63 patients who met the criteria were evaluated with transvaginal ultrasound and strain elastography mode of ultrasound. Before the measurements, strain elastography technique was defined and figures were added to ensure reproducibility. The strain measurements are displayed as a semitransparent color map called an elastogram, which is overlaid on the b-mode image. Typically, low strain (stiff tissue) is displayed in blue, and high strain (soft tissue) is displayed in red, although the color scale can vary depending on the ultrasound vendor. A pseudo-quantitative measurement called the strain ratio can be used, which is the ratio of strain measured in adjacent (usually normal) reference tissue region of interest (ROI) to strain measured in a target lesion ROI. SR >1 indicates that the target lesion compresses less than the normal reference tissue, indicating lower strain and greater stiffness. With these general information, cervix and uterus were examined in sagittal plane in all patients with transvaginal b-mode ultrasonography and elastography mode on the day before surgery. The size of the lesion in the cavity, the degree of myometrial invasion, possible presence of cervical and adnexal involvement were evaluated. The reason why the uterine cervix and intact myometrium were chosen as reference points is that they are adjacent to the target lesion and can be evaluated in the same window in elastography mode. After the elastography window was opened, the reference (intact myometrial area and cervical area) and target (endometrial lesion) ROI were determined, compression and decompressions cycles were applied with the transvaginal probe in one-second periods to create a pressure tracing. Strain ratio was calculated at the peak of the pressure in the area where the trace was regular. Comparison between intact myometrium and target tissue was defined as 'strain-corpus', while comparison between cervix and target tissue was defined as 'strain ratio-cervix'. Strain ratios were calculated at least 3 times and mean strain ratio was saved. All ultrasound examinations were performed by a single gynecologist oncologist and Voluson S8 (GE Healthcare, Wisconsin, USA) equipped with a 4.0-9.0 MHz multifrequency transvaginal probe was used for examination. When the definitive pathology results of the cases were reported in the postoperative period; tumor diameter, grade, myoinvasion, cervical involvement, lymph node metastasis and distant metastasis datas were recorded. According to the prognostic factors specified in pathology report, endometrial cancer risk groups defined by ESGO-ESMO-ESTRO guidelines were determined as a low- intermediate - high risk.
Datas were analyzed using SPSS 21.0 (SPSS, Chicago, IL, USA) statistical program. The distribution of continuous variables was analyzed with using visual and analytic method (Kolmogorov-Smirnov/Shapiro-Wilk test). Mean and standart deviations were used in normal distribution, while median and min-max values were used in non-normal distribution. Chi-square test was used to show the difference between categorical variables. Pearson and Spearman's rank correlation analyzes were used for continuous variables. Student-t Test and Kruskal Wallis analysis was used to compare the continuous variables in independent groups. The receiver operating characteristics (ROC) analysis was used to determine whether the mean strain ratio values had a statistically significant effect on the differentiation in prognostic factors. p < 0.05 was considered to indicate statistical significance.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Aydın, Turkey
- Adnan Menderes University Department of Gynaecologic Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with epitheliel endometrial cancer diagnosis with biopsy.
Exclusion Criteria:
- Diagnosis of different types of tumors in the last 5 years
- Presence of synchronous malignancy, presence of non epithelial uterine tumor
- Lack of patient data
- Presence of full-thickness uterine and cervical involvement (lack of evaluation for elastography)
- Lack of patient compliance for transvaginal ultrasound
- Inoperable cases (lack of definitive pathologic report)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
feasibility; to compare the stiffness and strain character of tumor tissue with well-known pathological prognostic factors of endometrial cancer.
Time Frame: strain ratio measurements of tumor tissue were performed one night before the operation. these data were compared with pathological reports which results 1 month after the cytoreductive surgery.
|
The strain measurements are displayed as a semitransparent color map called an elastogram, which is overlaid on the b-mode image.
Typically, low strain (stiff tissue) is displayed in blue, and high strain (soft tissue) is displayed in red, although the color scale can vary depending on the ultrasound vendor.
A pseudo-quantitative measurement called the strain ratio can be used, which is the ratio of strain measured in adjacent (usually normal) reference tissue region of interest (ROI) to strain measured in a target lesion ROI.
SR >1 indicates that the target lesion compresses less than the normal reference tissue, indicating lower strain and greater stiffness.The receiver operating characteristics (ROC) analysis was used to determine whether the mean strain ratio values had a statistically significant effect on the differentiation in well known pathological prognostic factors.
|
strain ratio measurements of tumor tissue were performed one night before the operation. these data were compared with pathological reports which results 1 month after the cytoreductive surgery.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-179
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Cancer
-
Radboud University Medical CenterMaastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis... and other collaboratorsRecruitingEndometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IVNetherlands
-
Assistance Publique - Hôpitaux de ParisUniversité Montpellier; Ecole d'econmie de Paris (PSE)-Hospinnomics; Université...CompletedEndometrial Cancer Stage I | Endometrial Cancer Stage IIFrance
-
Ain Shams Maternity HospitalNot yet recruitingTreatment Endometrial Cancer
-
Mayo ClinicRecruitingEndometrial Carcinoma | Stage III Endometrial Cancer | Stage IV Endometrial Cancer | Endometrial High Grade Endometrioid Adenocarcinoma | Stage II Endometrial CancerUnited States
-
Batman Training and Research HospitalEskisehir Osmangazi UniversityCompletedGynecologic Cancer | Endometrial Cancer Stage
-
Novartis PharmaceuticalsCompletedAdvanced Endometrial CancerBelgium, France, Italy, Canada, Spain, Australia, Germany, United States, Japan, Brazil, Singapore, Russian Federation, Poland
-
Rambam Health Care CampusCompletedSerous Papillary Endometrial CancerIsrael
-
University of Southern DenmarkDanish Cancer Society; Region of Southern DenmarkRecruitingEmpowerment, Cervical Cancer, Endometrial Cancer, Follow-up, Nurse-led, PROMDenmark
-
Memorial Sloan Kettering Cancer CenterRecruitingEndometrial Cancer | Endometrial Carcinoma | Stage III Endometrial Carcinoma | Stage III Endometrial Cancer | Endometrial Carcinoma Stage IIIUnited States
-
Samsung Medical CenterRecruitingEndometrial Cancer Stage IKorea, Republic of
Clinical Trials on Endometrial Cancer Survivors
-
Assiut UniversityRecruitingEndometrial Carcinoma | Clinicopathological | Federation of Gynecology and ObestetricsEgypt
-
Instituto Brasileiro de Controle do CancerRecruiting
-
University of MiamiAmerican Cancer Society, Inc.Completed
-
Duke UniversityNational Cancer Institute (NCI)CompletedMelanoma | Pain | Cancer | Breast Cancer | Fatigue | Psychological Distress | Germ Cell Tumor | Young Adult | Hematologic Cancer | Endocrine CancerUnited States
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
University of AlbertaCompletedSupervised Physical Activity Plus Exercise Counseling | Supervised Physical Activity Plus Behavioural CounselingCanada
-
Centre Hospitalier Universitaire VaudoisRecruitingEndometrial CancerSwitzerland
-
REHPA, The Danish Knowledge Centre for Rehabilitation...University of Southern Denmark; Region of Southern DenmarkCompleted
-
UNC Lineberger Comprehensive Cancer CenterCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompletedPediatric Cancer | Sequels | ComplicationsFrance